½ÃÀ庸°í¼­
»óǰÄÚµå
1541023

¼¼°èÀÇ º¹¸· Åõ¼® ½ÃÀå º¸°í¼­ : Ä¡·á À¯Çü, Á¦Ç°, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº°(2024-2032³â)

Peritoneal Dialysis Market Report by Treatment Type (Continuous Ambulatory Peritoneal Dialysis, Automated Peritoneal Dialysis ), Product, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 144 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è º¹¸· Åõ¼® ½ÃÀå ±Ô¸ð´Â 2023³â 173¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2024-2032³â 4.38%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸À̸ç 2032³â±îÁö 257¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù.

º¹¸· Åõ¼®(PD)Àº ½ÅºÎÀü Ä¡·áÀÇ ÀÏÁ¾À¸·Î, ¼ö¼ú·Î º¹°­ ³» ¶Ç´Â º¹ºÎ¿¡ ºÎµå·¯¿î ÇÃ¶ó½ºÆ½ Æ©ºê ¶Ç´Â Ä«Å×Å͸¦ »ðÀÔÇÏ´Â ¹æ¹ýÀÔ´Ï´Ù. Ä«Å×ÅͰ¡ »ðÀÔµÇ¸é ¹«±Õ ¼¼Á¤¾×ÀÌ ´öÆ®¸¦ ÅëÇØ ÁÖÀԵǾî ü³» Ç÷¾×À» ¿©°úÇÏ°í ³ëÆó¹°À» Á¦°ÅÇÕ´Ï´Ù. ÀÏÁ¤ ½Ã°£ÀÌ Áö³ª¸é ¾×ü¿Í ¿©°úµÈ ºÒÇÊ¿äÇÑ ¼ººÐÀº º¹ºÎ ¹ÛÀ¸·Î ¹èÃâµÇ¾î Æó±âµË´Ï´Ù. º¹¸· Åõ¼®Àº Áö¼ÓÀû ¿Ü·¡ º¹¸· Åõ¼®°ú Áö¼ÓÀû ¼øÈ¯½Ä º¹¸· Åõ¼®(CCPD)À¸·Î ±¸ºÐµË´Ï´Ù. ÀÌ·¯ÇÑ ¹æ¹ýÀº Ä¡·áÀÇ À¯¿¬¼ºÀ» Á¦°øÇϰí Åõ¼® ¼¾ÅÍ ¹æ¹®ÀÇ Çʿ伺À» ÁÙÀÌ¸ç ´õ ³ªÀº ÀÓ»ó °á°ú¸¦ °¡Á®¿À°í °á°úÀûÀ¸·Î ´õ ÀûÀº ¾à¹° º¹¿ë·®°ú ´õ ÀûÀº ½Ä»ç Á¦ÇÑÀ» °¡Á®¿É´Ï´Ù. ¶ÇÇÑ Áý¿¡¼­ ÇÒ ¼ö ÀÖ°í ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê±â ¶§¹®¿¡ º´¿ø°ú ÀÇ·á ¼¾ÅÍ¿¡¼­ ½ÅºÎÀü Ä¡·á¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

º¹¸· Åõ¼® ½ÃÀå µ¿Çâ :

°íÇ÷¾Ð, ´ç´¢º´, ¸»±â ½ÅºÎÀüÁõ(ESRD)ÀÇ À¯º´·ü Áõ°¡, ½ÅÀå ±âÁõÀÚ ºÎÁ·, ½ÅÀå À̽Ŀ¡ µû¸¥ À§Çè¿¡ ´ëÇÑ ¼ÒºñÀÚ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÅÀå ÀÌ½Ä ½ÃÀåÀÇ ¼ºÀåÀÌ Å©°Ô ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÈ÷ Äڷγª19 ÆÒµ¥¹Í »óȲ¿¡¼­ ÀçÅà Åõ¼® Ä¡·áÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÚµ¿ º¹¸· Åõ¼®(APD)°ú °°ÀÌ È¯ÀÚÀÇ ½ÅÀå ´ëü ¿ä¹ý ¹× ¾ß°£ ´ÙÁß ±³È¯À» À§ÇÑ ´Ù¾çÇÑ ±â¼úÀÇ ÃâÇöÀÌ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü Á¦Ç°Àº º¹¸·¿°°ú Å»Àå ¹ß»ý·üÀ» ³·Ãß°í, ƯÈ÷ ¸¸¼ºÄáÆÏº´(CKD)À» ¾Î°í ÀÖ´Â ³ë³âÃþ¿¡°Ô ´õ ³ªÀº ¹Ì·® ¿ëÁú Á¦°Å¸¦ Á¦°øÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºñ¿ë È¿À²ÀûÀÎ °¡°ÝÀ¸·Î ȯÀÚÀÇ À̵¿¼ºÀ» ³ôÀ̰í Áõ»óÀÇ º¯µ¿¼ºÀ» ÁÙÀ̱â À§ÇØ ÀÇ·áÁøÀÌ Ç÷¾× Åõ¼®º¸´Ù PD¸¦ ¼±È£Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ Á¤ºÎÀÇ ¿¬±¸°³¹ß(R&D)¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ ÅõÀÚ, °³¼±µÈ »óȯ Á¤Ã¥, Á¦Ç° ´Ù¾çÈ­ µîÀÌ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®µé

  • ¼¼°è º¹¸· Åõ¼® ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô ¼ºÀåÇØ¿Ô°í, ¾ÕÀ¸·Î ¾î¶»°Ô ¼ºÀåÇÒ °ÍÀΰ¡?
  • Äڷγª19´Â ¼¼°è º¹¸· Åõ¼® ½ÃÀå¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÃÆÀ»±î?
  • ÁÖ¿ä Áö¿ª ½ÃÀåÀº?
  • Ä¡·á À¯Çüº° ½ÃÀå ÇöȲÀº?
  • Á¦Ç°º° ½ÃÀå ºÐ¼®Àº?
  • ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ºÐ¼®Àº?
  • »ê¾÷ °¡Ä¡»ç½½ÀÇ ´Ù¾çÇÑ ´Ü°è´Â?
  • ¾÷°èÀÇ ÁÖ¿ä ÃËÁø¿äÀΰú °úÁ¦´Â?
  • ¼¼°è º¹¸· Åõ¼® ½ÃÀå ±¸Á¶¿Í ÁÖ¿ä ÁøÃâ ±â¾÷Àº?
  • ¾÷°èÀÇ °æÀïÀº ¾î´À Á¤µµÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ º¹¸· Åõ¼® ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : Ä¡·á À¯Çüº°

  • Áö¼Ó ÈÞ´ëÇü º¹¸· Åõ¼®(CAPD)
  • ÀÚµ¿ º¹¸· Åõ¼®(APD)

Á¦7Àå ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • º¹¸· Åõ¼®¾×
  • º¹¸· Åõ¼® Àåºñ
  • º¹¸· Åõ¼® ¼¼Æ®
  • º¹¸· Åõ¼® Ä«Å×ÅÍ
  • ±âŸ

Á¦8Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ÀçÅà Åõ¼®
  • Åõ¼® ¼¾ÅÍ ¹× º´¿ø ±â¹Ý Åõ¼®

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦10Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå PorterÀÇ Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Amecath
    • Baxter International Inc.
    • Fresenius Medical Care AG & Co. KGaA
    • Medical Components Inc.
    • Medionics International Inc.
    • Medtronic plc
    • Merit Medical Systems Inc.
    • Mitra Industries Pvt. Ltd.
    • Newsol Technologies Inc.
    • Nipro Canada(Nipro Medical Corporation)
    • Poly Medicure Limited
    • Terumo Corporation
    • Utah Medical Products Inc.
LSH 24.09.06

The global peritoneal dialysis market size reached US$ 17.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 25.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.38% during 2024-2032.

Peritoneal dialysis (PD) represents a type of kidney failure treatment procedure wherein a soft plastic tube or catheter is placed in the abdominal lining or belly through surgery. Once it is positioned, a sterile cleansing fluid is transmitted by the duct that helps filter the blood inside an individual's body by removing waste products. After a period of time, the liquid and filtered unwanted components flow out of the abdomen and are discarded. PD is differentiated into continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis (CCPD). These approaches offer treatment flexibility, reduce the need to visit dialysis centers, and provide better clinical outcomes, resulting in lesser medications and fewer food restrictions. Apart from this, it can be carried out at home and is needle-free; thus, PD is used by hospitals and healthcare centers to treat kidney failures.

Peritoneal Dialysis Market Trends:

The increasing prevalence of hypertension, diabetes, and end-stage renal disease (ESRD), the rising shortages of kidney donors, and the emerging awareness amongst consumers regarding the risks associated with kidney transplants are majorly driving the market growth. Moreover, the growing need for home dialysis treatments, especially during the COVID-19 pandemic, is acting as another growth-inducing factor. Furthermore, the advent of various technologies, such as automated peritoneal dialysis (APD), to perform renal replacement therapy for patients and multiple exchanges at night is contributing to the market growth. Such advanced products aid in lowering the incidences of peritonitis and hernias and offer better small solute clearances, especially to the geriatric population facing chronic kidney disease (CKD). Additionally, the shifting inclination of health practitioners toward PD over haemodialysis as it ensures greater patient mobility at cost-effective prices while creating fewer symptom fluctuations is propelling the market growth. Apart from this, extensive investments in research and development activities (R&D) by governments, improving reimbursement policies, and the ongoing product diversification are positively stimulating the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global peritoneal dialysis market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on treatment type, product and end user.

Breakup by Treatment Type:

Continuous Ambulatory Peritoneal Dialysis (CAPD)

Automated Peritoneal Dialysis (APD)

Breakup by Product:

Peritoneal Dialysis Solution

Peritoneal Dialysis Devices

Peritoneal Dialysis Sets

Peritoneal Dialysis Catheters

Others

Breakup by End User:

Home-based Dialysis

Dialysis Centers and Hospital-based Dialysis

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amecath, Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, Medical Components Inc., Medionics International Inc., Medtronic plc, Merit Medical Systems Inc., Mitra Industries Pvt. Ltd., Newsol Technologies Inc., Nipro Canada (Nipro Medical Corporation), Poly Medicure Limited, Terumo Corporation and Utah Medical Products Inc.

Key Questions Answered in This Report:

  • How has the global peritoneal dialysis market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global peritoneal dialysis market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global peritoneal dialysis market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Peritoneal Dialysis Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Continuous Ambulatory Peritoneal Dialysis (CAPD)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Automated Peritoneal Dialysis (APD)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Peritoneal Dialysis Solution
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Peritoneal Dialysis Devices
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Peritoneal Dialysis Sets
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Peritoneal Dialysis Catheters
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Home-based Dialysis
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Dialysis Centers and Hospital-based Dialysis
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amecath
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Baxter International Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Fresenius Medical Care AG & Co. KGaA
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Medical Components Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Medionics International Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Medtronic plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Merit Medical Systems Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Mitra Industries Pvt. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Newsol Technologies Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Nipro Canada (Nipro Medical Corporation)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Poly Medicure Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Terumo Corporation
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Utah Medical Products Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦